Inhibition of neurotensin-stimulated mast cell secretion and carboxypeptidase A activity by the peptide inhibitor of carboxypeptidase A and neurotensin-receptor antagonist SR 48692
- PMID: 9652308
- DOI: 10.1159/000023938
Inhibition of neurotensin-stimulated mast cell secretion and carboxypeptidase A activity by the peptide inhibitor of carboxypeptidase A and neurotensin-receptor antagonist SR 48692
Abstract
Background: Neurotensin (NT), a peptide found in brain and several peripheral tissues, is a potent stimulus for mast cell secretion and its actions are blocked by the specific NT receptor antagonist, SR 48692. Subsequent to stimulation, NT is rapidly degraded by mast cell carboxypeptidase A (CPA). In the experiments described here, we tested for the involvement of CPA activity in the activation of mast cell secretion by the peptide, NT.
Methods: Mast cells were isolated from the peritoneal and pleural cavities of rats, purified over metrizamide gradients and incubated at 37 degrees C in Locke solution or Locke containing the appropriate inhibitors. For some experiments, media derived from mast cells stimulated by compound 48/80 were used as a source of mast cell CPA activity.
Results: Treatment of mast cells with the highly specific peptide inhibitor of CPA derived from potato (PCI) inhibited histamine release in response to NT and NT8-13 (the biologically active region of NT). This inhibition required some 20 min to develop and was only partially reversed by a 20-min wash period. PCI (10 microM) did not inhibit histamine release in response to NT1-12, bradykinin, compound 48/80, the calcium ionophore, A23187, or anti-IgE serum. PCI also inhibited mast cell CPA activity. SR 48692, a highly selective antagonist of the brain NT receptor and of NT-stimulated mast cell secretion, also inhibited mast cell CPA activity as well as bovine pancreatic CPA activity in a concentration-dependent manner.
Discussion: It is suggested that the mast cell binding site for NT and the active site for CPA may share similar characteristics. The results are discussed in terms of NT mechanism of action on the mast cell.
Similar articles
-
Neurotensin stimulation of mast cell secretion is receptor-mediated, pertussis-toxin sensitive and requires activation of phospholipase C.Immunopharmacology. 1999 Feb;41(2):131-7. doi: 10.1016/s0162-3109(98)00064-2. Immunopharmacology. 1999. PMID: 10102794
-
Blockade of mast cell histamine secretion in response to neurotensin by SR 48692, a nonpeptide antagonist of the neurotensin brain receptor.Br J Pharmacol. 1995 Apr;114(7):1466-70. doi: 10.1111/j.1476-5381.1995.tb13371.x. Br J Pharmacol. 1995. PMID: 7541694 Free PMC article.
-
Inhibitory effects of the neurotensin8-13 analogs Asp13-NT8-13 and Asp12-NT8-13 on mast cell secretion.Agents Actions. 1993 Jan;38(1-2):1-7. doi: 10.1007/BF02027206. Agents Actions. 1993. PMID: 7683173
-
Characterization of the profile of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery.Neurosci Biobehav Rev. 2001 Dec;25(7-8):619-26. doi: 10.1016/s0149-7634(01)00045-8. Neurosci Biobehav Rev. 2001. PMID: 11801287 Review.
-
Chemistry-based design of inhibitors for carboxypeptidase A.Curr Top Med Chem. 2004;4(12):1217-26. doi: 10.2174/1568026043387908. Curr Top Med Chem. 2004. PMID: 15320722 Review.
Cited by
-
Nerve injury evoked loss of latexin expression in spinal cord neurons contributes to the development of neuropathic pain.PLoS One. 2011 Apr 29;6(4):e19270. doi: 10.1371/journal.pone.0019270. PLoS One. 2011. PMID: 21572518 Free PMC article.
-
Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis.Nat Med. 2008 Apr;14(4):392-8. doi: 10.1038/nm1738. Epub 2008 Mar 30. Nat Med. 2008. PMID: 18376408 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous